NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?

Novo Nordisk announced real-world STEER study data indicating its obesity drug Wegovy significantly reduced major adverse cardiovascular events (MACE) compared to Eli Lilly's tirzepatide in patients with overweight/obesity and established cardiovascular disease without diabetes. The study showed Wegovy achieved a 57% greater MACE reduction for consistent users and a 29% lower risk for all treated individuals, reinforcing its cardiovascular benefits and potentially boosting sales. This positions semaglutide as the only GLP-1 with proven CV protection for this specific patient group, enhancing Novo Nordisk's competitive standing in the lucrative GLP-1 market despite Eli Lilly's own efforts to expand tirzepatide's cardiovascular indications.

Analysis

Novo Nordisk (NVO) has reported positive real-world data from its STEER study, indicating Wegovy holds a significant advantage over Eli Lilly's (LLY) tirzepatide in reducing major adverse cardiovascular events (MACE) for patients with obesity and established cardiovascular disease without diabetes. Specifically, Wegovy demonstrated a 57% greater reduction in MACE for patients with consistent treatment adherence and a 29% lower risk of heart attack, stroke, or death across all users. This result reinforces Wegovy's clinical profile and establishes its active ingredient, semaglutide, as the sole GLP-1 therapy with this proven cardiovascular protection, potentially boosting future sales. However, this clinical success is sharply contrasted by NVO's market performance and analyst sentiment. The stock has underperformed its industry, sector, and the S&P 500, losing 34.4% year-to-date. Furthermore, earnings estimates for 2025 and 2026 have been revised downward over the past 60 days, from $3.90 to $3.84 and $4.58 to $4.09 per share, respectively, culminating in a Zacks Rank #5 (Strong Sell). Despite this, the company exhibits strong underlying profitability, with a trailing twelve-month return on equity of 78.64%, far exceeding the industry average of 34.32%. The stock trades at a discounted forward P/E of 14.09, well below its five-year mean, reflecting the prevailing negative market sentiment amidst a competitive landscape that includes not only LLY's efforts to secure its own cardiovascular indication for tirzepatide but also emerging late-stage candidates from players like Viking Therapeutics.

Key Decisions for Investors

• Investors should weigh the compelling long-term catalyst from Wegovy's superior cardiovascular data against Novo Nordisk's severe near-term headwinds, evidenced by its 34.4% year-to-date stock decline and downward revisions to 2025-2026 earnings estimates.
• Closely monitor Eli Lilly's progress toward a cardiovascular label expansion for tirzepatide, with submissions planned by the end of 2025, as this represents a direct and significant threat to Wegovy's newly established competitive advantage.
• The disconnect between NVO's discounted valuation (14.09 forward P/E) and its high return on equity (78.64%) may present a value thesis, but the 'Strong Sell' rating necessitates caution and a thorough risk assessment of continued negative market sentiment and intensifying competition.
• Consider the broader competitive landscape beyond the NVO-LLY duopoly, as other companies like Viking Therapeutics are advancing their pipelines, which could further fragment the obesity drug market and impact long-term growth prospects.